Clinical Trial Update: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating vorapaxar to attenuate D-dimer and target inflammatory and coagulation endpoints in HIV, completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Vorapaxar (vorapaxar)

Snippet

Sponsor: Kirby Institute | Conditions: HIV | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-28